Pfizer pays record fine for off-label promotion of four drugsBMJ 2009; 339 doi: http://dx.doi.org/10.1136/bmj.b3657 (Published 09 September 2009) Cite this as: BMJ 2009;339:b3657
- Janice Hopkins Tanne
- 1New York
Pfizer, the world’s largest drug company, has agreed to pay $2.3bn (£1.4bn; €1.6bn) to settle charges of fraud and civil and criminal liability over its promotion of off-label use of four drugs.
The US Department of Justice said it was the largest healthcare fraud settlement in the department’s history and the largest criminal fine ever.
The New York Times noted that $2.3bn amounted to less than three weeks of Pfizer sales (www.nytimes.com, 3 Sep, “Pfizer to pay $2.3 billion to settle inquiry over marketing”).
Unlike in previous settlements by drug companies, the announcement of the settlement was made at a Washington press conference by …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial